Related Experiment Videos
[Interferon-alpha2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple
J A Cabrera-Gómez1, N Echazábal-Santana, P Porrero-Martín
1Grupo Cubano para la Investigación y el Tratamiento de la Esclerosis Múltiple, Cienfuegos, Cuba. cabrera@jagua.cfg.sld.cu
Revista De Neurologia
|August 26, 2003
Summary
Interferon-alpha (IFN-alpha) treatment significantly improved cognitive dysfunction in relapsing remitting multiple sclerosis (RR-MS) patients. Higher doses of IFN-alpha demonstrated greater benefits in cognitive function compared to placebo.
Area of Science:
- Neuroscience
- Immunology
- Clinical Trials
Background:
- Relapsing remitting multiple sclerosis (RR-MS) is often associated with cognitive dysfunction.
- Preliminary studies suggest alpha-interferon (IFN-alpha) may be beneficial for RR-MS.
- Cuban reports indicated that 70% of MS patients experience cognitive impairment.
Purpose of the Study:
- To evaluate the efficacy of recombinant IFN-alpha2b in treating cognitive dysfunction in RR-MS patients.
- To compare the effects of low-dose and high-dose IFN-alpha2b against a placebo.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 57 RR-MS patients.
- Patients received intramuscular IFN-alpha2b (low or high dose) or placebo twice weekly for two years.
- Cognitive function was assessed using Luria, WAIS, Benton, and PASAT-3 tests.
Main Results:
- Both low-dose and high-dose IFN-alpha2b groups showed significant improvements in Luria, Benton, WAIS, and PASAT-3 test scores compared to placebo.
- Cognitive function in the placebo group showed no improvement or worsened across tests.
- No significant differences were observed between groups regarding age, gender, ethnicity, disease duration, or relapse rate.
Conclusions:
- IFN-alpha2b treatment effectively improved cognitive dysfunction in RR-MS patients.
- A higher dose of IFN-alpha2b appeared to yield more significant cognitive benefits.
- IFN-alpha represents a potential therapeutic option for cognitive impairment in RR-MS.